title: Therapeutic review: tuberculosis.
abstract: Tuberculosis (TB) is increasing in Zimbabwe and other countries in Africa and world-wide. TB treatment and control face new difficulties including the impact of the HIV epidemic and drug resistance. There is now abundant evidence that six-month regimens are highly effective and, by improving compliance, can improve results and the cost-effectiveness of therapy. Intermittent therapy reduces drug costs and allows for the possibility of complete supervision. The optimal management of the HIV-infected TB patient has not yet been established but an increased rate of drug reactions suggests that standard treatment should be reassessed.
authors.affiliation: Department of Clinical Pharmacology, University of Zimbabwe.
authors.forename: S
authors.initials: S
authors.lastname: Houston
authors.forename: A
authors.initials: A
authors.lastname: Pozniak
authors.forename: C S
authors.initials: CS
authors.lastname: Ray
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002985:Clinical Protocols / Q000592:standards*; D016527:Drug Costs; D015658:HIV Infections / Q000150:complications; D015497:HIV-1; D006801:Humans; D010349:Patient Compliance; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D015030:Zimbabwe / Q000453:epidemiology
chemical_list: D000995:Antitubercular Agents